Transcript Presentation 1 ACK Tick Committee

The Clinical Study Protocol for
Japanese Translators
Malcolm W. MacNab MD, PhD
President, Great Point Research LLC
Nantucket, MA
Annual Conference of the American Translators Association
October 2009
Clinical Development Documents

Investigator Brochure

Protocol

Protocol Amendments

Informed Consent

Investigator Letters

Study News Letters

Statistical Plan

Clinical Trial Report

Registration Documents
2
Clinical Study Protocol

The protocol describes the precise study plan for executing the trial:
• Scientific rationale;
• Objective(s)
• Design
• Methodology
• Statistical considerations
• Roles and responsibilities of all involved parties
• Operational details

The importance of a precise protocol:
• Assure safety and health of the trial subjects
• Exact template for trial conduct by investigators at multiple locations (in a
"multicenter" trial) to perform the study in exactly the same way
• Ability for data to be combined collectively from multiple sites
3
Today’s presentation

ICH – Harmonization of Clinical Development

The Clinical Development Process

The Protocol Development Process

The Clinical Protocol in Detail
4
ICH and GCP [1]

The International Conference on Harmonization of Technical
Requirements for the Registration of Pharmaceuticals for Human Use
(ICH)
• Established in 1990 as a joint regulatory/industry project to improve,
through harmonization, the efficiency of the process for developing and
registering new medicinal products in Europe, Japan and the United
States.

ICH established guidelines for how clinical trials should be conducted.
• Good Clinical Practice (GCP) is an international ethical and scientific
quality standard for:
- Designing;
- Conducting;
- Recording and reporting trials that involve the participation of human
subjects.
5
ICH and GCP [2]

Compliance with this standard provides public assurance that the rights,
safety and well-being of trial subjects are protected, consistent with the
principles that have their origin in the Declaration of Helsinki, and that the
clinical trial data are credible.
A set of ethical principles for the medical
community regarding human experimentation

Web location:
www.ich.org → Publications → Guidelines → Efficacy Guidelines (E)
→ E6(R1): PDF for GCP Guidelines
E6(R1) is the ‘bible’
Contains as glossary of key terms
for clinical research

Other Guidelines
• GMP: Good Manufacturing Practice
• GLP: Good Laboratory Practice
6
The Clinical Development Process
7
Clinical Studies
Types of clinical studies

Observational study
• Investigators observe the subjects and measure their outcomes
• The researchers do not actively manage the experiment

Interventional study
• Investigators give the research subjects a particular medicine or other
intervention
• Compare the treated subjects to subjects who receive no treatment
(placebo) or standard treatment
8
Clinical Studies
Pharmaceutical studies
Interventional studies
 Preferably should be:
• Double-blinded (masked)
– Phase I and pharmacokinetic studies may be open-label or single-blind
• Randomized
• Placebo controlled
– For ethical reasons, the placebo arm and the active treatment arm may
both be administered in conjunction with “standard therapy”
 Must studies are multicenter trails

• A clinical trial conducted according to a single protocol but at more than
one site - therefore, carried out by more than one investigator
9
Drug Development Process
Preclinical
Development
Preclinical
Testing in
animals
Clinical Development
Phase I
Phase II
Safety &
tolerability
Exploratory
safety &
efficacy
Phase III
Confirmatory
safety &
efficacy
Phase IV
Supportive of
approved
indication
Pharmacokinetic studies
Approval
Bridging study –
extrapolation of data from one region to another
10
Phase I Studies

First in humans – normal volunteers except for oncology

Purpose:
• To obtain an estimation of tolerability and safety – maximum tolerated dose
• To determination drug absorption, plasma drug levels and metabolic products
• Measurement of biomarkers if applicable

Involves approximately 20-100 subjects in 2 or 3 separate studies
11
Pharmacokinetic Studies [1]

Conducted throughout the development cycle

Purpose: To obtain information on drug absorption, plasma drug levels
and metabolic products

Each study usually involves 20 - 30 subjects
12
Pharmacokinetic Studies [2]

In addition to PK information obtained from Phase I, II and II studies, separate
studies may be conducted:
• Where there may be differences from the usual patient in the PK profile, such as:
– Elderly
– Children
– Hepatic dysfunction
– Renal dysfunction
• Drug interaction studies - to determine if other drugs used at the same time
produce a change in the PK profile
• Food interaction studies - to determine the effect of food on drug absorption
– May require a separate study in different regions
• Bioequivalence studies - to show that the PK profile has not changed if the drug
formulation has changed
• Bridging studies to determine is there are differences between patients in
different regions or ethnic differences
13
Phase II Studies

Purpose:
• Exploratory safety and efficacy in a particular indication in patients with
the disease or condition
• Controlled, randomized, double-blind trials
• Determine dose and duration of treatment for Phase III
• Confirm methodologies for Phase III – sample size, statistical methods,
endpoints, special studies
• Measurements of biomarkers and pharmacokinetics if applicable

Usually one study per indication

Involves approximately 100 - 250 patients
14
Phase III Studies
Purpose:
• Confirmatory studies based upon the results of Phase II
• To provide an adequate basis for marketing approval
 Referred to as “pivotal” or “registration studies”
 Focus
• Safety and efficacy
• Risk/benefit
• Assessment of sub-populations – age, race, sex
• Establish labeling for physicians
• Measurements of biomarkers and pharmacokinetics if applicable
 Usually two positive studies are required for regulatory approval
 Involves several thousand patients

15
Bridging Study [1]


Regulatory authorities must ensure that foreign clinical data can be adapted to
their region.
Ethnic differences may affect a medication’s safety, efficacy, dosage and dose
regimen.
Controversial: How significant are these
differences – if any?

Requirements for extensive duplication of clinical evaluation for every compound
can delay the availability of new therapies and unnecessarily waste drug
development resources.

Bridging Study: A supplemental study performed in the new region to provide
pharmacodynamic or clinical data on efficacy, safety, dosage and dose regimen
that will allow extrapolation of the foreign clinical data to the new region.

More important for foreign data being used in Japan than data collected in Japan
used in Europe or the US.
16
Bridging Study [2]

Bridging studies may be:
• Pharmacokinetic study comparing plasma drug levels and metabolic
products in subjects form the original region to subjects in the new
region; or
• Full clinical efficacy and safety study
17
Phase IV Studies

Conducted after the drug has received regulatory approval

Purpose:
• Post-marketing studies to delineate additional information including the drug's
risks, benefits, and optimal use

Examples:
• Collect additional safety data – sometimes required as a commitment to obtain
approval
• Explore other indications
• Pharmacoeconomics studies
• Quality of Life studies
• Scientific studies using endpoints not required for approval
• Comparative studies to other agents
18
Clinical Study Development

In the US and Europe, protocols to support drug registration are developed by the
study sponsor with input from outside experts, investigators and regulatory
agencies.

In Japan, protocols to support drug registration are often developed by the
investigator with input form the study sponsor, outside experts and the regulatory
agency.

“Investigator Initiated” studies
• Written and developed by investigators requesting financial support
• Usually Phase IV studies
• Almost never a pivotal registration study
19
Steps in developing a clinical protocol

Overall Project Development Plan - What information is needed to support the
proposed indication
• Active ingredient and drug product (formulation) production methods and
stability
• Animal toxicology
• Animal studies to support indication
• Clinical
– Safety
– Efficacy
– Pharmacokinetics
– Profiling – information to support the indication (e.g.. Biomarkers and
endpoints not accepted or needed for approval but important to the
medical/scientific community)

PROTOCOL DEVELOPMENT
20
Steps in developing a clinical protocol & study initiation
Input from past studies
Input from:
Manufacture Study Drugs
• Phase I: Information from preclinical studies
• Regulatory requirements
/ Test Products
• Phase II: Dose selection form Phase I
• Phase III: Dose, safety, validated endpoints
from Phase II
• Regulatory Authorities
• Active
• Medical experts
• Placebo
Write protocol
• Study investigators
Write Informed Consent, Design CRFs
Build Data Base
Formal meeting with Regulatory
Authorities – usually at the
Select study sites
end of Phase II
Blinding and packaging
Ship to study sites
Study site activities
• Contract approval
• Protocol & Informed Consent
approval by IRB/EC
Investigator Meeting
GCP & Protocol training
Study initiation
21
The Clinical Protocol in Detail
22
ICH – GCP Guidelines for Clinical Protocols (E6-R1)
The following contents should be defined in a written protocol:

General Information

Background Information

Trial Objective and Purpose

Trial Design

Selection and Withdrawal of
Subjects

Direct Access to Source
Data/Documents

Quality Control and Quality
Assurance

Ethics

Data Handling and Record Keeping

Treatment of Subjects

Financing and Insurance

Assessment of Efficacy

Publication Policy

Assessment of Safety

[Study Administration]

Statistics
23
Study Personnel [1]

Principal Investigator (PI)
• Usually a “KOL” – Key Opinion Leader; individual considered a leader in
his/her field
• Overall responsibility for the study across multiple sites
• The model is used in Japan for most studies
• Not always used in the US and Europe - used for large studies (e.g.. “outcome”
studies); studies managed by academic cooperative groups

Coordinating Committee or Steering Committee or Executive Committee
• A committee that a sponsor may organize to coordinate the conduct of a
multicentre trial
• Consists of KOLs and Sponsor representative
• Usually for large “outcome” studies
• Act on recommendations of the Data and Safety Monitoring Board (DSMB) and
Endpoint Committee; review and approval of publications/presentations
24
Study Personnel [2]

Independent Data and Safety Monitoring Board (DSMB) or Independent
Data-Monitoring Committee (IDMC)
• independent data-monitoring committee that may be established by the sponsor
to:
- Overseeing the welfare of study subjects enrolled in the trial
- Review safety data – partially unblinded “A” vs. “B” or un-blinded
• NO Sponsor membership – members include KOLs and an independent
statistician
• Usually for large “outcome” studies or when there is concern about a specific
side-effect

Endpoint Committee
•
Provide an independent and blinded assessment of the efficacy endpoints as
defined by the protocol, based on the standardized classification and
definitions.
25
Study Personnel [3]
“Qualified” person
……..obtained from the hospital pharmacy or other local qualified pharmacy source…….
……..Study drug will be administered by qualified study staff only in accordance with the procedures
described in this protocol…….
……..Qualified study staff at the site will collect and document study data…….
……..The investigator is required to sign (electronically or hard copy) the eCRF to verify that he/she has
reviewed the recorded data and confirms the accuracy of the data. This review and sign-off may be
delegated to a qualified physician appointed as a Sub Investigator by the Investigator……
Individuals involved in the study have the appropriate education, training, and experience to assume
responsibility for the proper conduct of the study
The investigator for a heart failure trial should be a cardiologist, not another specialty
The Study Site personnel should have appropriate certification and training; i.e. study tests
should not conducted by the secretary
Laboratories used in the study have the appropriate certification
All individuals (Study Site personnel, Study Monitors, In-house Sponsor personnel, pharmacists etc.)
must have training in the protocol and GCP procedures
26
Study Personnel [4]
Study Site Personnel

Investigator: “qualified” physician
• Overall responsibility of protocol execution at the study site
- Obtain subject informed consent
- Safety of subjects
- Supervision of study personnel
- Approval and sign-off of all CRF

Study Coordinator: usually a “qualified” nurse
• Individual who manages the study at the local site – person who actually “does the
work” – not the investigator
- Screens subjects for eligibility
- Collects and manages study data
- Manages paper work
- Subject follow-up
27
Study Personnel [5]
Sponsor Personnel

Medical Expert or Medical Monitor: “qualified” physician
• Overall responsibility for the study and subject safety
• Answers medical and safety question related to the protocol

Study Monitor
• Visits Study sites to ensure compliance with the protocol
• Appropriately trained, and should have the scientific and/or clinical knowledge
needed to monitor the study adequately
28
Study Personnel [6]
Sponsor Personnel

Contract Research Organization (CRO)
• Sponsor may delegate all or part of their responsibilities to a third party
- Monitoring, data management, Medical Expert, protocol development, report
writing, statistics etc.
• Maybe referred in the protocol as “Sponsor representative” or by the specific
name of the CRO
• Commercial for-profit organizations and non-profit academic organizations [e.g..
Duke Clinical Research Institute (DCRI), Eastern Cooperative Oncology Group
(ECOG)]
29
Study Objectives

What the study wants to show with the
appropriate subject numbers,
statistics, and design
Primary:
To evaluate the safety and efficacy of translatium in subjects diagnosed with diastolic heart
failure. The primary variable for assessing efficacy will be assessment of exercise tolerance
using the Six-minute walk test. Exploratory – information will be supportive
but not necessarily definitive – avoids
“data dredging”

Secondary:
To evaluate the efficacy of translatium on the measurements listed below:
• Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score
• New York Heart Association (NYHA) classification
• Carboxymethyllysine (CML)

Tertiary:
To evaluate the efficacy of translatium on the measurements listed below:
• Number of hospitalizations due to heart failure
• Number of cardiovascular deaths
Exploratory – information will be
• Number of all-cause deaths
supportive but not necessarily definitive
– avoids “data dredging”
• B-type natriuretic peptide (BNP)
30
Assessment of Efficacy
Study objectives are outlined in detail in the ‘Assessment of Efficacy’ section
……. A Six-minute walk test will be performed at the Screening Visit (Visit 1) to ensure that subjects can
walk at least 100 meters, but not more than 450 meters. The baseline measurement for analysis will be
performed at Visit 2 and repeated at 3 months on treatment (Visit 5) and at 6 months of treatment
(Visit 7). The walking test will be performed based upon the guidelines of the American Thoracic Society.
The distance walked by subjects will be recorded in meters. See Appendix 2 for additional details…….
Pharmacodynamic Endpoints
The study of the physiological effects of drugs and the
mechanisms of drug action and the relationship between
drug concentration and effect; pharmacodynamic (PD) –
pharmacokinetic (PK) - PDPK determination.
…….. A plasma sample for Carboxymethyllysine (CML) will be obtained 30 minutes before the initial
dose of study drug and at 1 hour after the initial dose of study drug. CML will also be obtained at 30
minutes before the last dose of study drug and at 1 hour after the last dose of study drugs.
………A plasma sample for B-type natriuretic peptide (BNP) will be measured 30 minutes before the initial
dose of study drug and 30 minutes after the last dose of study drug...........
31
Treatment of Subjects
Call-in system for
randomization
Randomization
…….Verification of receipt and condition of study medications are to be entered in the interactive voice
response (IVR) system. The IVR system will assign a study medication kit number to the subject that
corresponds to a number that is listed on the label for the drug kit that is to be given to the subject. The
investigator will be provided a telephone number, fax number or web log-in and a specific identification
and password code to give in order to enter the subject’s specific information for randomization. The IVR
system will assign a code that is a coded assignment to the study medication for that subject. There will be
a faxed or emailed confirmation of the code corresponding to the study medication assigned to the subject.
The code for the study medication assignment must be recorded in the subject case report form (CRF). In
the event a subject drops out prior to randomization, the subject number is never re-used. Codes are never
re-assigned. Randomization records are never re-used…………

IVRS
• Randomize across study sites
• Best for stratification
• Best for drug supply management
32
Treatment of Subjects
Randomization
Subject 001: B
A
Subject 002: B
Subject 003: A
Subject 004: B
B
Subject 005: A
Subject 006: A
33
Assessment of Safety [1]

Adverse Drug Reaction (ADR)
• All noxious and unintended responses to a medicinal product related to any dose.
• A causal relationship between a medicinal product and an adverse event is at least a
reasonable possibility, i.e. the relationship cannot be ruled out.

Adverse Event (AE)
• Any unintended or undesirable experience that occurs during the course of the clinical
investigation regardless of drug relationship.
• May occur in the drug under investigation, placebo or comparative agent (active control).

Serious Adverse Event (SAE) or Serious Adverse Drug Reaction (Serious ADR)
• Any untoward medical occurrence that at any dose:
- results in death
- is life-threatening
- requires inpatient hospitalization or prolongation of existing hospitalization
- results in persistent or significant disability/incapacity
- is a congenital anomaly/birth defect
34
Assessment of Safety [2]
Reporting of Adverse Drug Reactions is a problematic area As a result, protocols tend to have lengthy sections on the topic
including sections on what is not an AE

Some investigators make very strict calls about AEs, others do not

Asian studies tend to have fewer AEs reported
• Cultural?

Errors of “Causality” assignment by investigators
• Disease related as opposed to drug related, sometimes hard to call;
e.g. Myocardial infarction or death in a trial to study a drug for
myocardial infarction patients
35
Assessment of Safety [3]
Reporting of Adverse Drug Reactions is a problematic area –

Investigators often request the un-blinding of an AE when it is not necessary

Objective laboratory data does not match the reported clinical event

SAEs are mistakenly reported as AEs, not reported at all or not reported in a
timely manner
• There are strict regulatory requirements for reporting SAEs to Regulatory
Authorities

Multiple terms for the same event are used across study sites and regions to report
AEs
36
Assessment of Safety [4]
The Medical Dictionary for Regulatory Activities Terminology (MedDRA)

Developed under the auspices of ICH to used to classify adverse event information associated
with the use of biopharmaceuticals and other medical products

Coding these data to a standard set of MedDRA terms
• Minimizes the need for interpretation at data entry
• Allows for a more readily exchange and analysis data
• Permits a more accurate combination of information form different studies and different
regions
• Ensures that a given adverse reaction is accurately reported
Reported Event
Hyperglycemia
Increased blood sugar
Blood glucose high
Increasing glucose
Nephritis interstitial
Tubulointerstitial nephritis
MedDRA preferred term (PT)
Hyperglycemia
Tubulointerstitial nephritis
37
Statistical Methods
‘Null hypothesis’ –
there is no effect
‘Alternative hypothesis’ –
there is an effect
……The primary hypothesis of interest is:
Variability to characterize
the dispersion among the
measures in a given
population.
H0: μ2 = μ1 vs. H1: μ2 ≠ μ1
where μ2 is the mean change in 6 minute walk distance over the duration of the study for the treatment group
subjects and μ1 is mean change in 6 minute walk over the duration of the study for control group subjects.
Under the assumptions that (a) μ1 = 10 m and μ2 = 14 m, and (b) that the standard deviation of changes is 7,
then a sample size of 72 in the treatment group and 72 in the control group will yield 90% power to detect
a significant difference between the two groups, using a two-sample Wilcoxon rank-sum test at a two-sided
0.05 level of significance. To account for approximately 10% dropout, 80 subjects will be enrolled in each
group…….
Probability of rejecting the hypothesis
tested when in fact, that hypothesis is
true – there is no difference when there
is difference in treatments – alpha (ά ) –
‘p value’
Probability that the test will reject the
hypothesis tested when a specific
alternative hypothesis is true – there is
difference in treatments.
38
Data Handling and Record Keeping
Collection and Transmission of Data
Representative of the Sponsor who visits the
study site at regular intervals – “Study
Monitor”; “Clinical Research Associate”;
“Monitor”
•Ensures compliance with the protocol
•Ensures compliance with GCP standards
Usually a nurse – received specific
training on the protocol – “Study
Coordinator”
•Verification of source data as entered on
CRF
•Study medication accountability
..........Qualified study staff at the site will collect and document study data. The Sponsor’s representative
will perform clinical monitoring, including review of data captured in the eCRFs with verification to the
appropriate source documentation...........
The raw data from subject’s medical chart,
clinic notes, lab reports, ECGs, X ray
reports, hospital charts etc.
39
Data Handling and Record Keeping


Collection and Transmission of Data – Case Report Form (CRF)
A paper or electronic questionnaire used to collect data for each subject from each
participating site.
• Demographic data
• Inclusion and exclusion data
• Adverse events
• Special laboratory and procedures – most lab routine lab data are transmitted
electronically for the lab to the sponsor
• Efficacy data
The paper CRFs are sent to the sponsor and the information entered into the Study
Data Base
OR

The data are entered directly into the Study Data Base at the Study Site using a
secured online system – Electronic CRF (eCRF)
40
Data Handling and Record Keeping - CRFs
41
Data Handling and Record Keeping
Queries

Queries are non-sensible or questionable data that must be explained
• . Examples:
– Confusion between ‘pounds’ and kilo grams’
– Missing data from CRF/eCRF
– Events not reported as Adverse Experiences
– Young person with stroke or hip fracture
– ‘Hypoglycemia’ reported but lab report lists glucose as ‘normal’
42
Ethics
Privacy
............The investigator must assure that subjects' anonymity will be maintained. On all documents submitted
to the Sponsor, subjects will be identified by a unique subject identification number; subjects should
not be identified by name.......
GCP requirement - Institutional Review Board or sometimes
.
referred as Independent Ethics Committee (IEC) –
Independent Board at each study site responsible for local
approval of investigations in humans
........... The investigator agrees to supply the Sponsor or its designee with evidence of IRB approval, a copy of
the informed consent form which is IRB-approved, and a copy of any modified informed consent form later
approved by the IRB and used by the investigator. The investigator also agrees to keep the IRB informed
as to the progress of the study as well as to any serious and unexpected adverse events. As part of, or in
addition to the informed consent, the investigator shall obtain from each subject a research authorization, as
defined in the privacy regulations (the “Privacy Regulations”) promulgated pursuant to the Health
Insurance Portability and Accountability Act of 1996 (HIPAA) ....................................
In USA studies only – USA law to ensure patient privacy – ‘Covered Entities’
(physicians, laboratories, hospitals, insurance companies) may not release
medical information without patients consent.
43
Study Administration
Study Closeout - Final Visit by the Study Monitor to the Study Site
......Upon completion of the study, defined by all subjects having completed all follow up visits,
all CRFs completed, and all queries resolved, the Sponsor’s representative will notify the site
of closeout and a study closeout visit will be performed. All CRFs and any unused study
materials will be returned to the Sponsor’s representative. The Study Monitor will ensure
that the Investigator’s regulatory files are up to date and complete, and that any outstanding
issues from previous visits have been resolved. Other issues to be reviewed at the closeout
visit include: discussing retention of study files, possibility of site audits, publication policy,
and notifying the IRB/EC of study closure............
44
Study Administration
Audit/Inspections – Monitoring
Overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in
accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP),
and the applicable regulatory requirement(s)
• Focus on the conduct of the trial

• Conducted by: Study Monitor visits, Sponsor Medical Expert, Steering Committee
Monitoring
……As part of a concerted effort to follow the study in a detailed and orderly manner in accordance with
established principles of Good Clinical Practice (GCP) and applicable regulations, a Study Monitor will
visit the site regularly and will maintain frequent telephone and written communication…….

Audit
……The Sponsor or their representative Quality Assurance personnel may conduct audits at the study site(s).
Audits will include, but not be limited to: audit trail of data handling and processes, SOPs, drug supply,
presence of required documents, the informed consent process, and comparison of case report
forms/database with source documents…………Regulatory authorities worldwide may also audit the
Investigator during or after the study……….
A systematic and independent examination of trial related activities and documents to determine
whether the evaluated trial related activities were conducted in accordance with SOPs, GCP and the
applicable regulatory requirements.
• Focus on procedures for all parties (Sponsor, Investigator, CROs, Study Site etc.)
• Conducted by: Sponsor QA Department, Regulatory Authorities
45
Questions ?
46